
usd jul pm et
summari lead biotech compani major treatment anemia neutropenia
rheumatoid psoriat arthriti psoriasi cancer osteoporosi
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
see sale declin
billion billion expect
legaci product continu face headwind
off-set growth newer product
aimovig prolia xgeva kyproli
repatha sale grew yoy
million boost inclus posit
cardiovascular outcom data prescrib
inform fda approv repatha
decemb first inhibitor
prevent heart attack stroke late
octob cut repatha price
lower pocket cost
patient ultim bolster demand
expect repatha sale grow
approxim million volum growth
expect oper margin
due lower sale leverag pipelin
invest expens associ
product launch expect
priorit capit spend pipelin
expans develop long-term
revenu growth opportun
billion remain stock
repurchas author march
significantli yoy
think share trade
ep estim near fair
valu sale matur drug declin
growth new product ramp
robust pipelin exclud
phase ii program phase program
year-end expect biosimilar
crucial growth driver particularli
compani recent launch outsid
 sale kanjinti biosimilar herceptin
amgevita biosimilar humira
also work promis drug develop
program address kra
mutat previous thought
undrugg occur mani cancer
lung adenocarcinoma
expect share phase dose escal
data earli june
risk recommend target
includ pipelin failur inabl obtain new
drug approv difficulti obtain
reimburs third-parti payer
target base
ep estim
multipl near averag
risk assess reflect particip
highli competit regul market subject
chang govern reimburs polici
drug safeti oversight see risk mitig
diversifi product roster gener robust
cash flow support share repurchas cash dividend
new asset acquisit
oct ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview amgen inc one largest biotechnolog compani world
compani commit unlock potenti biolog patient suffer seriou ill
discov develop manufactur deliv innov human therapeut approach
begin use tool like advanc human genet unravel complex diseas understand
fundament human biolog
compani product sale three major wholesal -- cardin
-- account total revenu year end decemb
combin basi wholesal account amgn gross product sale
year end decemb respect
world-wide gross revenu year
billion product sale gener largest contributor drug
enbrel neulasta prolia aranesp xgeva sensipar/mimpara
sale gener februari least phase drug
develop program phase ii program phase program
competit environ oper highli competit environ number
market product indic diseas area product treatment current
avail pursu amgn competitor research develop activ
addit competitor-market product target genet pathway amgn recent
launch market product pursu current competit could impact price
market share product continu pursu way increas valu medicin
innov life cycl includ expand diseas area
amgn product indic find new method make deliveri amgn medicin easier
less costli activ offer import opportun differenti
certain exist patent amgn princip product expir compani face new
increas competit includ biosimilar gener may also compet
biosimilar gener version competitor product biosimilar anoth version biolog
product market approv sought obtain base demonstr
highli similar origin refer product believ advers impact amgn product
sale biosimilar competit like brand biolog competit seen
brand small molecul face gener although expect biosimilar compet price mani
patient provid payer may continu place high valu reput reliabl safeti
product alreadi use decemb competitor approv
biosimilar version epogen neulasta enbrel
major develop given compani wide pipelin product portfolio compani frequent
signific develop highlight signific recent develop
may announc work promis drug develop program
address kra mutat occur lung adenocarcinoma
common form non-smal cell lung cancer colon cancer low single-digit percent
cancer well mutat undrugg past year
may fda approv aimovig novel treatment develop migrain prevent aimovig
self-administ monthli devic sureclick autoinjector requir
septemb announc deal regard humira key
drug biosimilar amjevita deal grant licens humira intellectu properti
licens begin januari began octob europ
fda european commiss approv repatha treatment adult
hypercholesterolemia high cholesterol patent litig past year
regeneron sanofi regard compet hypercholesterolemia drug praluent
financi trend gener billion revenu reflect growth
year-over-year compound annual growth rate compound-annual-growth-rate compani adjust ep
grew year-over-year reflect compound-annual-growth-rate compani low level
debt net debt total capit march gener billion free
cash flow billion given compani cash flow robust balanc
sheet believ compani continu fund program market
activit forese futur
oper
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc juli technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit outlook biotechnolog
histor defens sub-industri
expect see commerci
develop mani new innov therapi
declin preval patent
expir biotechnolog
compani trade discount
market think remedi
robust pipelin new drug brought
market fda approv novel drug increas
shatter
previou record sinc novel
approv set think mani
drug either newly-approv
late-stag clinic trial consider
commerci prospect repres major
advanc therapi diseas
sclerosi cancer
pace deal slower
mega-d announc
acquisit celgen celg
acquisit botox manufactur
allergan industri debt level
still low risen last five year
cheap see sever matur
biopharmaceut firm made
mark blockbust drug look
off-set lost revenu expir patent
fail ventur promis late-stag
pipelin addit exampl see gilead
scienc like
acquir expect
interest off-set declin hcv
therapi sale expect engag
 activ make failur
biotechnolog compani low debt level
attract valuat rel
industri make favor
think growth biotechnolog
stock limit recent high
drug price come
heighten scrutini polit
apparatu last year despit
talk lower drug price
seen particularli sever measur taken
legisl regulatori bodi
lower drug price democrat took
hous repres
novemb mid-term elect appear
motiv address drug price
still think suffici impetu
effect signific chang near
futur anoth sourc price pressur
drug manufactur pharmaci benefit
manag pbm health insur
exert influenc drug
prescript price pressur
like increas major pbm merg
major insur cvs-aet ci-esrx
biolog price competit innov
act bpcia grant
exclus period brand biolog maker
sinc brand biolog manufactur
aggress use patent law
commerci leverag delay
commerci biosimilar
maintain market domin longer
result expect biosimilar continu
advanc slowli next sever year
year-to-d june
biotechnolog index risen mere
compar rise valu
 composit index
declin
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target slightli peer
forward ep estim slower-than-p growth
ep vs ahead view aid lower tax rate
lower number share outstand rais ep estim
ep estim sale rose new product
sale -- includ prolia kyproli xgeva --
partial off-set continu sale declin matur product
best-sel drug enbrel declin neulasta sale flat aimovig
recent approv fda treat migrain encount issu
third-parti payer pharmaci benefit manag regard price
set patient assist program provid free two-month trial
aimovig negoti payer on-going say complet
contract obtain coverag cover live /jeffrey loo cfa
et cfra keep hold opinion share inc
keep target line peer
ep estim rais ep estim
ep vs ahead view sale
rose new product grow least sale top
drug neulasta fell enbrel fell expect fda approv
migrain drug aimovig next month note express script esrx largest
pharmaci benefit manag pbm indic may limit access drug due
anticip high list price exr suggest
reason gross-to-net price would reduc rebat esrx also
said ask refund drug work within defin time
period expect third parti payer exert pressur drug price
cholesterol drug repatha face similar challeng limit
sale sale grow though still well
analyst research note compani news
et cfra keep hold opinion share amgen inc
maintain target base
averag forward price-to-earnings ep estim ep
vs beat consensu estim take ep
ep sale
declin billion driven increas competit due patent
expir repurchas billion worth share
expect lift share repurchas billion
promis kra inhibitor continu focal point
like import valuat program progress
rapidli complet enrol monotherapi expans cohort
enrol non-smal cell lung cancer patient combin
arm sandoz litig best-sel enbrel continu
overhang share opinion especi sinc decis expect soon
et cfra maintain hold opinion share amgen inc
lower target
ep estim multipl reflect averag
forward pe rang ep vs
slightli estim lower ep
ep sale flat
year-over-year billion product sale declin line
expect repurchas billion worth share compani
intend repurchas anoth billion work
promis drug develop program address kra
mutat occur lung adenocarcinoma
common form non-smal cell lung cancer colon cancer low
single-digit percent cancer well drug
treatment mutat past year expect share
phase dose escal data earli june /kevin huang cfa
pm et cfra maintain hold opinion share amgen inc
lower target
ep estim multipl near averag
three-year forward pe rang ep vs
higher estim lower ep
initi ep revenu increas billion
total product sale increas billion oper
margin decreas oper expens increas driven
higher spend support earli oncolog pipelin
late-stag develop higher sg expens invest product
launch market product support expect priorit
capit spend pipelin expans develop long-term revenu
growth opportun also still remain author billion
common stock repurchas /kevin huang cfa
et cfra maintain hold opinion share inc
lift target
ep estim multipl near middl rang
ep vs higher
estim rais ep ep
revenu increas billion total product
sale increas billion growth newer product bare off-set
declin matur declin product sale recent
launch aimovig exceed expect patient
start aimovig base health care profession late
octob cut price one key new drug repatha
lower pocket cost patient bolster demand
oper margin decreas oper expens increas
driven spend sg expens invest product launch
market product support /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
